Molecular diagnosis of spinal muscular atrophy

H Stewart, A Wallace, J McGaughran, R Mountford, H Kingston

Abstract
The frequency of deletions within the survival motor neurone (SMN) and neuronal apoptosis inhibitory protein (NAIP) genes in patients with spinal muscular atrophy (SMA), and the impact of this on the diagnosis and prenatal diagnosis of SMA, were investigated by molecular analysis of stored DNA and retrospective review of case notes. In type I SMA, 16 of 17 cases were homozygously deleted for exons 7 and 8 of SMN, 14 of 17 were homozygously deleted for exon 5 of NAIP, and 13 of 17 were deleted for both. In types II and III SMA, seven of nine cases were deleted for exons 7 and 8 of SMN. Deletions of SMN and NAIP occurred in four of nine cases. With one exception, the deletion genotypes of probands, affected siblings, and terminated fetuses were identical. Molecular studies are replacing conventional investigations for SMA and have a high uptake prenatally.

(Keywords: spinal muscular atrophy; survival motor neurone gene; neuronal apoptosis inhibitory protein gene; molecular diagnosis)

The spinal muscular atrophies (SMAs) form a heterogeneous group of diseases inherited as autosomal dominant, autosomal recessive, or X linked recessive traits. The childhood onset autosomal recessive form affects between one in 6000 and one in 10 000 live births and is the second most common lethal autosomal recessive disorder in white people after cystic fibrosis. The carrier frequency is one in 60–80 in the UK.

The characteristic pathology of SMA is degeneration of motor neurones in the anterior horn of the spinal cord and, in some cases, motor nuclei in the brain stem, resulting in muscular atrophy and progressive paralysis. Recent studies have advanced the understanding of the possible mechanisms involved in the pathogenesis of SMA. A novel protein (SMN) is located in the cytoplasm and in novel nuclear bodies called gems. SMN is found at high concentrations in motor neurones and the spinal cord in normal subjects but at reduced concentrations in patients with SMA. SMN is associated with another novel protein (SIP1). These proteins are thought to play a role in the metabolism of small nuclear RNAs. However, their role in motor neurone degeneration remains undetermined.

There are three clinical subtypes of autosomal recessive SMA. Type I (Werdnig-Hoffmann disease) is the most severe, with onset in utero, with reduced fetal movements, or in the first six months of life, with hypotonia, wasting, fasciculation, paucity of movement, and areflexia. Affected children have normal intelligence but are unable to sit unaided, have feeding difficulties, and die from respiratory failure or aspiration before the age of 2 years. Type II is of intermediate severity. Patients have hypotonia, delayed motor milestones, are able to sit unsupported, but cannot stand or walk unaided. Complications include scoliosis and feeding difficulties. Survival depends on the degree of respiratory muscle involvement but is usually greater than 4 years. Type III (Kugelberg-Welander disease) has an onset after the age of two and patients are able to walk unaided, although they do so late, fall frequently, and have a shuffling gait, foot drop, and difficulty with stairs. Slow deterioration results in scoliosis and wheelchair dependence.

The diagnosis is confirmed by muscle biopsy (showing degeneration of muscle fibres, in the absence of inflammation, fibrosis, or histochemical abnormality) and electromyelography (EMG) (showing denervation, paucity of movement, and fasciculation). These procedures are invasive, time consuming, and may give inconclusive results when performed in young infants. Findings in cerebrospinal fluid, serum enzymes, and nerve conduction are normal.

In 1990, 95% of cases of all three recessive forms of SMA were found to be linked to the 5q13 region of chromosome 5. This enabled prenatal prediction on the basis of linkage in some families. Deletion events within this region were found to be associated with SMA, and in 1995, two candidate genes within this region were postulated: the survival motor neurone (SMN) and neuronal apoptosis inhibitory protein (NAIP) genes. This region of the genome is complex and inherently unstable, with two almost identical copies of SMN, one centromeric and one telomeric, and multiple copies of pseudogenes of NAIP (fig 1).

Homzygous deletions of exons 7 and 8 of the telomeric (functional) copy of SMN occur in > 95% of patients with SMA but not in normal control populations. Short deletions in the consensus splice sites of introns 6 and 7,

Centromeric copy Telomeric copy

<table>
<thead>
<tr>
<th>NAIP</th>
<th>SMN^COPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMN^SMA</td>
<td>NAIP</td>
</tr>
</tbody>
</table>

Figure 1 Map of chromosome 5q13.
and point mutations, have been found in a Vogue individuals who do not have homozygous deletions of exons 7 and 8 of SMN, confirming that SMN has a role in the aetiology of SMA.

16 19 The exact role of deletionsof SMN is not clear, as illustrated by the following observations: una Vogue parents and siblings have homozygous deletions of exons 7 and 8 of SMN in 1% of cases 20; parents of children with types II and IIISMA may have more than two copies of the centromeric copy of SMN and it has been postulated that this might have an effect on the phenotype 21; 4% of normal people are homozygously deleted for the centromeric copy of SMN, so it is not known whether this copy of the gene has any function. 17 18 Deletions of exon 5 of NAIP occur in 67% of patients with type I SMA, 42% of those with types II and III, and 2–3% of controls. 22 23 The role of this gene in the aetiology of SMA remains obscure, although it is thought that larger deletions involving SMN and NAIP are associated with increased disease severity. 22 23 Deletion analysis of SMN has been used for prenatal diagnosis and has largely replaced linkage analysis. As the deletion in the proband arises de novo in 1% of patients with SMA, errors could be made in prenatal predictions based only on linkage analysis in subsequent pregnancies. 24–26

The purpose of our study was to confirm the frequency of deletions within SMN and NAIP in patients with known SMA, to establish the pattern of deletions in affected siblings, to confirm that fetuses terminated on the basis of linkage had deletions within these genes, and to review how this information can aid patients and clinicians in diagnosing SMA prenatally and in childhood.

Methods

SUBJECTS

We included in our study all patients referred to our department before August 1996, in whom the diagnosis of SMA was confirmed clinically, their affected siblings, and those fetuses terminated following prenatal diagnosis. The patients came from a variety of different ethnic origins.

Molecular Analysis

DNA was extracted from peripheral blood lymphocytes on an Applied Biosystems 380A DNA extractor or from stored Guthrie cards by cutting a 3 mm² fragment of card with a sterile scalpel, boiling the fragment in 100 µl of 50 mM sodium hydroxide for 20 minutes, then neutralising with 15 µl of 1.0M Tris, pH 8.0. 27 Polymerase chain reaction (PCR) amplification of SMN exons 7 and 8, and NAIP exons 5 and 13 was carried out in 10 µl volumes using 25 ng of genomic DNA, 5 pmol each of forward and reverse primers, 750 µmol/l of each dNTP, 0.2 U Taq polymerase (Gibco BRL, Paisley, UK) in a PCR buffer comprising 3.7 mM MgCl₂. PCR was carried out on a Techne PHC-2 using the following cycling parameters: initial denaturation at 94°C for three minutes; 30 cycles of 94°C for one minute, 60°C for one minute, and 72°C for one minute; and a final synthesis of 72°C for 10 minutes. Owing to the low yield of DNA from Guthrie cards, PCR was extended to 35 cycles. PCR products from NAIP were loaded on to 2% agarose gels stained with ethidium bromide, run in 1× Tris borate EDTA (TBE) buffer and visualised under UV light. Exon 13 of NAIP was analysed as a control.

Single strand conformation dependent polymorphism analysis (SSCP) was used to investigate exons 7 and 8 of SMN. SSCP is a simple, sensitive technique in which DNA is amplified by PCR then samples are denatured and loaded on to a non-denaturing polyacrylamide gel. Single stranded DNA has a tendency to fold to form complex structures with different electrophoretic properties depending on their

| Table 1  Results of DNA deletion analysis |
|---------|---------|---------|--------|
| Type I | Types II and III | All types |
| SMN exons 7 and 8 | 16/17 (94%)* | 7/9 (78%) | 23/26 (88.5%) |
| NAIP exon 5 | 14/17 (82%) | 4/9 (44%) | 18/26 (69%) |
| Both | 13/17 (76%) | 4/9 (44%) | 17/26 (65%) |

*Remaining patient was deleted for exon 8 of SMN and exon 5 of NAIP.

Figure 2 (A) Agarose gel showing polymerase chain reaction (PCR) analysis of neuronal apoptosis inhibitory protein (NAIP) genes. Lane 1, normal control, both exons 5 and 13 amplify. Lanes 2 and 3, both patient samples. Lane 2, homozygous deletion of exon 5, normal exon 13 supporting a diagnosis of spinal muscular atrophy (SMA); lane 3, no deletion of exon 5. (B) Single strand conformation dependent polymorphism analysis (SSCP) analysis of survival motor neurone (SMN) exons 7 and 8. Lane 1, control sample homozygously deleted for SMN functional gene; lane 2, normal control; lane 3, patient homozygously deleted for exons 7 and 8 of the functional SMN gene, confirming the diagnosis of SMA; lanes 4 and 5, normal pattern, excluding the diagnosis of SMA; lane 6, control sample homozygously deleted for the non-functional SMN gene.
conformation, which in turn depends on the DNA sequence. In this case, deleted and normal exons 7 and 8 of the telomeric and centromeric copies of SMN have different mobilities and are, therefore, easily distinguished in affected patients and controls. PCR products were run on 8% polyacrylamide gels in 1x TBE buffer then visualised by silver staining.28

Case notes were reviewed retrospectively.

**Results**

**Type I**

There were 17 probands, six affected siblings, and four terminated fetuses. Of the 23 children, 11 were girls and 12 were boys. There was consanguinity in five of 17 families. The dates of birth ranged from 1969 to 1995. The mean age of onset was stated in 16 children and ranged from birth to 6 months, with a mean of 2.4 months. The age at diagnosis was known in 16 children and ranged from 1 month to 7 months, with a mean of 4.1 months. In one case, where parents declined invasive investigations in 1989, the diagnosis was not confirmed until 1996, when a DNA test was performed on a stored neonatal blood spot. All 23 children died at 2 to 16 months, with a mean of 4.1 months. Three of the 23 children had muscle biopsy and EMG findings. One additional patient, who was not included in this study, had late onset SMA confirmed by muscle biopsy and EMG and was found to have deletions of exons 7 and 8 of SMN on one chromosome 5 and a gene conversion event (involving a C to T transition at nucleotide 873 but not nucleotide 868–44) in exon 7 of the telomeric copy of SMN on the other chromosome 5. This transition occurred at a site critical for correct splicing of exon 7, and rendered the gene non-functional. Gene conversion events in exon 7 have been reported previously.18

There were three affected siblings from two families. All three were shown to have the same SMN deletion as the index cases. In one case, the proband was homozygously deleted for NAIP but the sibling was not, owing to recombination. No fetuses were terminated.

Muscle biopsy and/or EMG was performed in 11 of 12 cases and results are shown in table 2. One case was diagnosed by DNA analysis alone.

Three families had no further children after diagnosis of the proband. The pregnancies occurring in the remaining six families are summarised in table 3.

**Discussion**

The genetics of autosomal recessive SMA are complicated and the correlation between genotype and phenotype remains obscure.4–21–23 Despite this, in general, identification of homozygous deletions of exons 7 and 8 of SMN in a child with symptoms can be considered diagnostic and can avoid the need for invasive muscle biopsy and EMG testing.26–27

Our series of patients included children diagnosed before DNA tests were available and in one case analysis was performed on DNA extracted with parental consent from a stored neonatal blood spot card. In 12 cases, blood samples had been taken during life and DNA

**Table 1**

<table>
<thead>
<tr>
<th>Types of investigations</th>
<th>Biopsy (n = 1)</th>
<th>EMG (n = 1)</th>
<th>Total (n = 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>7</td>
<td>9</td>
<td>16</td>
</tr>
<tr>
<td>Atypical, but compatible</td>
<td>4</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Atypical</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Normal</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

*Linkage results subsequently confirmed by deletion testing; †no prenatal test performed.

**Table 2**

<table>
<thead>
<tr>
<th>Types of investigations</th>
<th>Biopsy (n = 10)</th>
<th>EMG (n = 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Atypical, but compatible</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Atypical</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Normal</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

**Table 3**

<table>
<thead>
<tr>
<th>Type</th>
<th>Number of pregnancies</th>
<th>Number of tests</th>
<th>Number of affected children</th>
<th>Number of terminations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>II and III</td>
<td>10</td>
<td>7*</td>
<td>3†</td>
<td>3*</td>
</tr>
<tr>
<td>II and III</td>
<td>8</td>
<td>8</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Linkage results subsequently confirmed by deletion testing; †no prenatal test performed.
stored in anticipation of future tests becoming available.

We observed an overall frequency of 88.5% for deletions within the SMN gene compared with 95% in previous reports. Of 17 probands with type I SMA, 16 were homozygously deleted for exons 7 and 8 of SMN and the remaining patient was deleted for exon 8 only. Of the nine probands with type II and III SMA, seven had homozygous deletions of exons 7 and 8 of SMN. The frequency of deletions within the NAIP gene was 82% in type I and 44% in types II and III compared with previously reported frequencies of 67% and 42%, respectively. Discrepancies between observed and reported figures may be a result of our small sample size. The sensitivity of DNA deletion tests in confirming the diagnosis of SMA compares favourably with that of muscle biopsy (16 of 21) and EMG (15 of 22). Of four cases of SMA in our series diagnosed since 1995, only one has undergone a muscle biopsy; one was diagnosed on EMG and DNA analysis and two have been diagnosed on DNA analysis alone. The specificity of DNA testing is reflected in reported figures of <1% of unaffected relatives with homozygous deletions of SMN and 2–3% of non-SMN chromosomes having deletions of NAIP.

DNA analysis is particularly useful in confirming the diagnosis of SMA in cases with atypical clinical features or atypical results on muscle biopsy or EMG. Severe neonatal SMA with diaphragmatic paralysis has been reported in two siblings discordant for DNA markers flanking the SMA locus, suggesting that this form of SMA maps outside the 5q11.2–q13.3 region. In our series of patients, there were two babies with neonatal onset of severe SMA with early respiratory problems who died at 8 and 10 weeks. The muscle biopsy in both was not typical of SMA, but was thought to be compatible with the diagnosis when the early timing of the investigations was taken into account. Both patients had EMGs showing active denervation, consistent with SMA. Subsequent analysis of DNA in both cases revealed homozygous deletions of exons 7 and 8 of SMN, confirming the diagnosis and the validity of a prenatal test that had been performed by linkage analysis in one of the families. Both patients were also homozygously deleted for exon 5 of NAIP, which is compatible with their severe phenotype.

In general, the limitations of linkage analysis as a result of non-informativeness or recombination can be resolved by the more direct deletion testing. In our series, two children at risk of SMA type II had predictive tests performed by DNA linkage analysis during the first 6 months of life. In both cases prenatal testing had been declined. The first child was calculated to be at 3.5% risk of being affected. Later, he developed symptoms of SMA and the diagnosis was confirmed by open muscle biopsy at 13 months of age. Further linkage analysis using closer markers confirmed that the affected child had inherited the same SMA linked haplotypes as the older affected sibling, indicating that a recombination had occurred between the disease locus and the original DNA markers used. Subsequent analysis confirmed homozygous deletion of exons 7 and 8 of SMN in both siblings. In the second family, the child was tested after birth and found to have inherited the same high risk chromosomes as her affected sibling. Unlike her sibling, however, she was not homozygously deleted for exons 7 and 8 of SMN. It was concluded that only one parent was a carrier for SMA and that the other parent had germline mosaicism for the deletion or that an additional de novo deletion had arisen in the affected child.

In our series, there was a high uptake of prenatal prediction by linkage alone (eight of 15 pregnancies) and of prenatal diagnosis by both deletion testing and linkage (eight of eight pregnancies). This reflects the high level of acceptability of prenatal diagnosis and termination of affected pregnancy reported previously.

The pattern of SMN and NAIP deletions in affected siblings and terminated fetuses was identical to that in the proband except in one case where a recombination was known to have occurred, resulting in deletion of SMN but not NAIP in the second affected sibling. Previously, consistency of the deletion has been assumed for SMN deletions but not documented. Conversely, there are reports of siblings with identical SMN deletions who are not concordant for symptoms of SMA (types II/III). This is sufficiently rare that the demonstration of a homozygous deletion of SMN in the presence of symptoms of SMA can be assumed to confirm the diagnosis. In the context of prenatal diagnosis, it is not possible to confirm the phenotype of the fetus, and diagnosis relies solely on determining the presence or absence of the mutation known to cause SMA in the affected sibling. In our series, all fetuses predicted to be affected by linkage analysis have had the presence of homozygous deletions confirmed by subsequent analysis. All fetuses predicted to be unaffected by prenatal linkage or deletion testing have remained healthy after birth.

We thank Drs M Clarke, M Noronha, and P Tomlin for the clinical evaluation and diagnosis of the patients in this study and for referring them for genetic assessment. The muscle biopsies were reported by Drs A Kelsey and P Lynch. Financial support for this study was provided through an Innovative Development Grant from the NHS Executive North West.

Key messages
- All patients should be clinically assessed by a paediatric neurologist.
- DNA should be analysed in all cases of suspected spinal muscular atrophy.
- Counselling should be offered as well as prenatal diagnosis via linkage and deletion testing.
- Samples should be stored for future mutation testing.

Molecular diagnosis of spinal muscular atrophy


In the genetic disorder spinal muscular atrophy, causative gene mutations are found in the SMN (survival motor neuron) gene. The SMN gene is located on chromosome 5q13 and is responsible for encoding the SMN protein, which is essential for spliceosome function. Mutations in the SMN gene lead to the loss of SMN protein, resulting in the characteristic clinical features of spinal muscular atrophy.

Several studies have investigated the genetic basis of spinal muscular atrophy, focusing on genomic deletions in the SMN gene. These deletions can be detected using deletion analysis, which involves the identification of specific deletion polymorphisms. The presence of these deletions can be used to predict the SMA phenotype in affected individuals.

In addition to deletion analysis, SNP (single nucleotide polymorphism) analysis has been used to identify genetic markers associated with spinal muscular atrophy. These markers can be used to identify individuals at risk for developing the disease and to map the disease locus on chromosome 5q13.

Overall, the genetic basis of spinal muscular atrophy is complex and involves multiple candidate genes. However, the identification of the SMN gene and the development of genetic testing methods have significantly advanced our understanding of this disease and have improved the diagnostic and management strategies for patients with spinal muscular atrophy.
Molecular diagnosis of spinal muscular atrophy

H Stewart, A Wallace, J McGaughran, R Mountford and H Kingston

Arch Dis Child 1998 78: 531-535
doi: 10.1136/adc.78.6.531

Updated information and services can be found at:
http://adc.bmj.com/content/78/6/531

These include:

References
This article cites 26 articles, 12 of which you can access for free at:
http://adc.bmj.com/content/78/6/531#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Motor neurone disease (10)
Neuromuscular disease (166)
Pregnancy (528)
Reproductive medicine (945)
Molecular genetics (111)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/